Your browser doesn't support javascript.
loading
An evaluation of continuous subcutaneous infusions across seven NHS acute hospitals: is there potential for 48-hour infusions?
Baker, J; Dickman, A; Mason, S; Bickerstaff, M; Jackson, R; McArdle, A; Lawrence, I; Stephenson, F; Paton, N; Kirk, J; Waters, B; Ellershaw, J.
Afiliación
  • Baker J; Pharmacy Department, Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK. J.baker6@nhs.net.
  • Dickman A; Palliative Care Institute Liverpool, University of Liverpool, Liverpool, UK. J.baker6@nhs.net.
  • Mason S; Pharmacy Department, Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK.
  • Bickerstaff M; Palliative Care Institute Liverpool, University of Liverpool, Liverpool, UK.
  • Jackson R; Palliative Care Institute Liverpool, University of Liverpool, Liverpool, UK.
  • McArdle A; Liverpool Clinical Trials Unit, University of Liverpool, Liverpool, UK.
  • Lawrence I; Liverpool Clinical Trials Unit, University of Liverpool, Liverpool, UK.
  • Stephenson F; Pharmacy Department, Wirral University Teaching Hospital NHS Foundation Trust, Wirral, UK.
  • Paton N; Pharmacy Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Kirk J; Pharmacy Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Waters B; Pharmacy Department, The Christie NHS Foundation Trust, Manchester, UK.
  • Ellershaw J; Pharmacy Department, St Helens and Knowsley Teaching Hospitals NHS Trust, Prescot, UK.
BMC Palliat Care ; 19(1): 99, 2020 Jul 07.
Article en En | MEDLINE | ID: mdl-32635902
BACKGROUND: Continuous subcutaneous infusions (CSCIs) are commonly used in the United Kingdom as a way of administering medication to patients requiring symptom control when the oral route is compromised. These infusions are typically administered over 24 h due to currently available safety data. The ability to deliver prescribed medication by CSCI over 48 h may have numerous benefits in both patient care and health service resource utilisation. This service evaluation aims to identify the frequency at which CSCI prescriptions are altered at NHS Acute Hospitals. METHODS: Pharmacists or members of palliative care teams at seven acute NHS hospitals recorded anonymised prescription data relating to the drug combination(s), doses, diluent and compatibility of CSCIs containing two or more drugs on a daily basis for a minimum of 2 days, to a maximum of 7 days. RESULTS: A total of 1301 prescriptions from 288 patients were recorded across the seven sites, yielding 584 discrete drug combinations. Of the 584 combinations, 91% (n = 533) included an opioid. The 10 most-common CSCI drug combinations represented 37% of the combinations recorded. Median duration of an unchanged CSCI prescription across all sites was 2 days. CONCLUSION: Data suggests medication delivered by CSCI over 48 h may be a viable option. Before a clinical feasibility study can be undertaken, a pharmacoeconomic assessment and robust chemical and microbiological stability data will be required, as will the assessment of the perceptions from clinical staff, patients and their families on the acceptability of such a change in practice.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infusiones Subcutáneas / Hospitales Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: BMC Palliat Care Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infusiones Subcutáneas / Hospitales Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: BMC Palliat Care Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido